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ABSTRACT
Thrombotic microangiopathy (TMA) may occur after allogeneic hematopoietic stem cell transplantation
(HSCT) and is related in part to calcineurin inhibitor toxicity. We observed a higher-than-expected rate of
TMA when calcineurin inhibitors were combined with sirolimus. To determine the incidence of and risk
factors for TMA after HSCT, we performed a retrospective cohort analysis of myeloablative allogeneic HSCT
recipients between 1997 and 2003. TMA diagnosis required the simultaneous occurrence of (1) creatinine
increase >2 mg/dL or >50% above baseline, (2) schistocytosis, (3) increased lactate dehydrogenase, and (4) no
evidence of disseminated intravascular coagulopathy. A total of 111 sirolimus-exposed subjects were compared
with 216 nonexposed subjects after HSCT. TMA occurred in 10.8% of the sirolimus group and 4.2% in the
nonsirolimus group (odds ratio, 2.79; P  .03). Sirolimus exposure was associated with TMA earlier than in
nonsirolimus patients (25 versus 58 days; P  .04). Only the use of sirolimus (exact odds ratio, 3.49; P  .02)
and grade II to IV acute graft-versus-host disease (exact odds ratio, 6.60; P .0002) were associated with TMA
in regression analyses. Treatment of TMA varied among affected individuals. Renal recovery was complete in
92% of sirolimus-treated patients. Overall survival after TMA diagnosis was better for sirolimus subjects than
for nonsirolimus subjects (58.3% versus 11.1%; P  .02). Sirolimus seems to potentiate the effects of
calcineurin inhibitors on TMA after HSCT. TMA associated with sirolimus seems reversible and has a
favorable prognosis when compared with TMA associated with calcineurin inhibitors alone. A careful moni-
toring strategy for TMA should be used with a sirolimus-containing graft-versus-host disease prophylaxis
regimen.
© 2005 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Despite signiﬁcant advances in allogeneic hema-
opoietic stem cell transplantation (HSCT), graft-ver-
us-host disease (GVHD) and transplant-related tox-
city remain as 2 important hurdles to improved
utcomes. GVHD prophylaxis with the combination
f methotrexate and a calcineurin inhibitor has re-
ained the most commonly used regimen for almosta.C. and N.L.H. contributed equally to this article.
B &MTdecades [1]. Methotrexate is associated with signif-
cant transplant-related toxicity, including mucositis
2], pulmonary toxicity [3], and delayed engraftment
4,5]. The calcineurin inhibitors have been associated
ith neurologic toxicity, renal dysfunction, and
hrombotic microangiopathy (TMA) after transplan-
ation [6-8]. TMA is a syndrome of microangiopathic
emolytic anemia, thrombocytopenia, and renal dys-
unction, although the exact deﬁnition varies in dif-
erent published studies of the syndrome [9-13]. The
ssociation of TMA with cyclosporine and tacrolimus
551
a
e
e
l
c
i
t
t
h
b
r
r
c
s
n
c
p
w
b
I
f
M
S
s
t
s
t
d
t
c
i
g
p
o
(
S
c
w
c
m
T
o
b
p
(
c
S
t
i
l
a
a
l
2
b
d
p
p
c
t
r
v
p
w
n
t
p
c
d
a
p
o
o
d
m
c
c
R
t
T
m
b
s
b
h
a
w
T
o
t
c
c
o
O
c
p
C. Cutler et al.
5fter stem cell and solid-organ transplantation is well
stablished [9-12,14,15].
Numerous attempts have been made to develop an
ffective GVHD prophylaxis regimen associated with
ess transplant-related toxicity [16-19]. A novel macro-
yclic lactone, sirolimus, has been found to have potent
mmunosuppressive effects in solid-organ transplanta-
ion [20-23] and has been studied in stem cell transplan-
ation [24,25]. The use of sirolimus and calcineurin in-
ibitors in solid-organ and stem cell transplantation has
een associated with TMA, [26-31] and there is 1 case
eport of TMA related to sirolimus monotherapy in a
enal transplant patient [26].
In 2 clinical trials of sirolimus in allogeneic stem
ell transplantation, GVHD control was noted to be
uperior to historical controls; however, TMA was
oted to occur with increased frequency [24,25]. Be-
ause of this apparent increase in TMA incidence, we
erformed a retrospective cohort study of patients
ho underwent allogeneic stem cell transplantation
etween 1997 and 2003 at the Dana Farber Cancer
nstitute to determine the incidence of and risk factors
or TMA.
ATERIALS AND METHODS
tudy Design
This was a retrospective single-center cohort analy-
is of patients who underwent allogeneic HSCT be-
ween 1997 and 2003. Patients were included in the
tudy cohort if they received sirolimus as a component of
heir GVHD prophylaxis regimen during the ﬁrst 100
ays after transplantation and were included in the con-
rol cohort if sirolimus was not used. All patients re-
eived either a cyclosporine-based or a tacrolimus-based
mmunosuppressive regimen. Patients who had under-
one prior HSCT, who had T-cell depletion as GVHD
rophylaxis, whose baseline creatinine was1.5 mg/dL,
r who had a diagnosis of severe veno-occlusive disease
VOD) of the liver were excluded from this analysis.
ubjects for the case and control populations were ac-
rued concurrently, although sirolimus-exposed subjects
ere accrued from 2000 onward only. Case and control
ohort subjects were identiﬁed by review of electronic
edical records.
MA Definition
TMA was deﬁned as the simultaneous occurrence
f (1) creatinine increase2.0 mg/dL or50% above
aseline, (2) schistocytosis (2 schistocytes per high-
ower ﬁeld), (3) increased lactate dehydrogenase, and
4) no clinical evidence of disseminated intravascular
oagulopathy.
tatistical Analysis
A 2-sided Fisher exact test was used to compare
he baseline characteristics, acute GVHD, and the T
52ncidence of TMA between the 2 treatment cohorts. A
ogistic regression model was used to estimate the
ssociation of treatment groups and TMA incidence,
djusting for other factors. Overall survival was calcu-
ated by using the Kaplan-Meier method, and a
-sided log-rank test was used to test the difference
etween survival curves.
Demographic (age and sex) and hematologic (un-
erlying disease and remission status at time of trans-
lantation) disease variables were recorded for each
atient. Transplantation characteristics recorded in-
luded the conditioning regimen, donor characteris-
ics (age, sex, HLA matched versus mismatched, and
elated versus unrelated), graft type (bone marrow
ersus peripheral blood stem cells), and GVHD pro-
hylaxis regimen used. Multiple laboratory values
ere also recorded for all patients, including creati-
ine, unfractionated lactate dehydrogenase, coagula-
ion parameters, and the presence of schistocytes on
eripheral blood smear. Outcome parameters re-
orded included the occurrence of GVHD, VOD, and
iffuse alveolar hemorrhage. Information gathered for
ll patients with TMA included the time from trans-
lantation to the onset of TMA; peak creatinine; levels
f tacrolimus, cyclosporine, and sirolimus at the onset
f TMA; neurologic and cardiac signs at the time of
iagnosis; treatment administered for TMA; develop-
ent of chronic renal insufﬁciency; and the need for
hronic hemodialysis. Finally, overall survival was re-
orded for all patients in this analysis.
ESULTS
A total of 111 and 216 subjects were included in
he sirolimus and nonsirolimus groups, respectively.
he baseline characteristics of the subjects are sum-
arized in Table 1. The 2 groups of subjects were
alanced for demographic parameters; however, more
ubjects in the sirolimus group received peripheral
lood stem cells (50.5% versus 18.1%; P  .01) and
ad unrelated donors (58.6% versus 42.6%; P  .01).
During the 6-year period of this retrospective
nalysis, 21 subjects were identiﬁed as having TMA
ithin the ﬁrst 100 days after allogeneic HSCT.
welve subjects (10.8%) in the sirolimus group devel-
ped TMA, in comparison with 9 subjects (4.2%) in
he nonsirolimus group (odds ratio [OR], 2.79; 95%
onﬁdence interval [CI], 1.14-6.84; P  .03). Not all
ases of TMA were recognized clinically at the time of
nset.
nset and Symptoms of TMA
The median time to develop TMA in the sirolimus
ohort was 25 days from the time of HSCT, in com-
arison with 58 days for the control group (P  .01;
able 2). In addition to the requisite symptoms and
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Bigns deﬁning TMA, 6 subjects in each group devel-
ped mental status changes, 2 subjects in each group
eveloped congestive heart failure, and 2 subjects in
he study group and 3 subjects in the control group
eveloped seizures.
Levels of the calcineurin inhibitors and sirolimus
ere assayed routinely. The median number of assays
n the 2 weeks before TMA diagnosis were 5 (siroli-
us), 6 (tacrolimus measurements in the sirolimus
roup), (5.5 tacrolimus measurements in the nonsi-
olimus group), and 5 (cyclosporine measurements in
he nonsirolimus group). The median trough tacroli-
us levels immediately before the onset of TMA were
imilar in the 2 groups (sirolimus group, 9.9 ng/mL;
ontrol group, 9.1 ng/mL; P  not signiﬁcant). In
atients treated with cyclosporine, the median trough
evel was 418 g/L (range, 93-469 g/L). In patients
able 1. Demographic Characteristics of Patients
Characteristic Sirolimu
ample size 111
edian age, y (range) 40 (18–6
ale, n (%) 63 (56.8
ource of stem cells, n (%)
PBSC 56 (50.5
Bone marrow 55 (49.5
Bone marrow and PBSC
onor type, n (%)
MRD 40 (36%
URD 45 (40.5
Mismatched related 6 (5.4%
Mismatched URD 20 (18%
VHD prophylaxis, n (%)
Sirolimus  tacrolimus  Mtx 111 (100%
Tacrolimus  Mtx  other
Cyclosporine  Mtx  other
Other/unknown
cute GVHD
Grade 0-I 84 (77.1
Grade II-IV 25 (22.9
BSC indicates peripheral blood stem cells; MRD, matched rel
Mtx, methotrexate.
able 2. Clinical Characteristics of TMA
Variable Sirolimus Non-Sirolimus
ncidence 12 (10.8%) 9 (4.2%)*
edian day of onset (range) 25 (11-69) 58 (17-91)†
edian peak creatinine
(mg/dl) (range) 3.9 (2.1-9.3) 2.5 (2.3-5.7)
ental status changes 6 (50%) 6 (67%)
eizures 2 (17%) 3 (33%)
ongestive heart failure 2 (17%) 2 (22%)
edian sirolimus level
(ng/mL) (range) 6.1 (2.5-33.0) —
edian tacrolimus level
(ng/mL) (range) 9.9 (2.8-27.4) 9.1 (8.2-12.1)
edian cyclosporine level
(g/L) (range) — 418 (93-469)
Odds ratio, 2.79; P  .03.
P  .04. ‡
B&MTreated with sirolimus, the median level was 6.1 ng/
L, which is within the target range for our institu-
ion (3-12 ng/mL). Of the 9 sirolimus users at the time
f TMA diagnosis, 7 had median levels within the
herapeutic range.
herapy of TMA
Most affected individuals were treated by dose
djustments or discontinuation of the calcineurin in-
ibitor, sirolimus, or both (Table 3). Of the 12 sub-
ects in the study group, calcineurin inhibitors were
iscontinued in 4 subjects, and the doses were de-
reased in 6 subjects. Two subjects were initially
witched from tacrolimus to cyclosporine, although
yclosporine was discontinued in 1 patient within
Non-Sirolimus P Value
216
41 (18–66) .46
117 (54.2%) .72
39 (18.1%)
176 (81.5%)
1 (0.5%) <.001
115 (53.2%)
70 (32.4%)
9 (4.2%)
22 (10.2%) .007
0
92 (42.6%)
119 (55.1%)
5 (2.3%)
142 (70.6%)
59 (29.4%) .28
nor; URD, unrelated donor; GVHD, graft-versus-host disease;
able 3. Therapy and Outcome of TMA
Variable Sirolimus Non-Sirolimus
top calcineurin inhibitor 5 (42%)* 3 (33%)
hange to different calcineurin
inhibitor 1 (8%) 0
iscontinue sirolimus 1 (8%) N/A
lasma exchange 1 (8%) 2 (22%)
emodialysis or CRRT 3 (25%) 4 (44%)
hronic kidney disease† 1 (8%) 2 (22%)
ialysis dependent 1 (8%) 0 (0%)
eath within 4 wk 3 (25%) 5 (56%)
urvival after TMA diagnosis 58.3% 11.1%‡
RRT indicates chronic renal replacement therapy; N/A, not
applicable.
Includes one patient who changed to a different calcineurin inhib-
itor but subsequently discontinued all calcineurin inhibitors.
Chronic kidney disease was deﬁned by a persistent increase of
serum creatinine 2 mg/dL.s
2)
%)
%)
%)
)
%)
)
)
)
%)
%)
ated doP  .02.
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5ays. One patient discontinued sirolimus, 8 subjects
ontinued to receive sirolimus, and 3 subjects had
reviously discontinued sirolimus. Of the 9 subjects in
he control group, 3 subjects discontinued calcineurin
nhibitors, and the other 6 subjects continued dose-
djusted calcineurin inhibitors.
Two subjects in each group required temporary
emodialysis. One patient who received sirolimus and
who did not were also treated with plasma exchange.
he decision to institute plasma exchange was at the
iscretion of the treating physician.
MA Outcome
Of the 9 subjects treated with sirolimus who sur-
ived more than 4 weeks after the onset of TMA, all
egained normal renal function after resolution of
MA, including 1 patient treated with plasma ex-
hange. The median time to a return of a creatinine
evel 2.0 mg/dL was 11 days (range, 4-17 days).
hree patients in the sirolimus group required renal
eplacement therapy for 3, 7, and 25 days. One subject
eveloped chronic renal insufﬁciency approximately 1
ear after transplantation and after initial near-nor-
alization of renal function. His renal biopsy sample
evealed severe arterial sclerosis consistent with
hronic microangiopathy. He is currently dialysis de-
endent. Five of 9 patients in the control group died
ithin 4 weeks of TMA diagnosis. The single long-
erm survivor in the control group has chronic renal
nsufﬁciency.
Survival after TMA diagnosis was better for pa-
ients treated with sirolimus than for those who did
ot receive sirolimus (3-year survival, 58.3% versus
1.1%; log-rank P  .02; Figure 1). The median
urvival after diagnosis of TMA in the study group has
ot been reached, but it was 22 days in the control
igure 1. Survival analysis of patients from the time of thrombotic
icroangiopathy diagnosis. Survival in the sirolimus cohort was
uperior to that of the nonsirolimus cohort (58.3% versus 11.1%;
 .02).roup. Among sirolimus-treated individuals, the cause k
54f death was related to GVHD in 4 patients and to
ultisystem organ failure in the ﬁfth. The diagnosis of
VHD predated the diagnosis of TMA by 5 to 29
ays in this group, and all patients died with concom-
tant infections. Among non–sirolimus-treated pa-
ients, the cause of death was GVHD in 4, sepsis in 2,
nd TMA alone or with GVHD in the remaining 2.
he 2 deaths at least partially attributable to TMA
ere in individuals who were given sirolimus to con-
rol or prevent GVHD after the diagnosis of TMA.
isk Factors for TMA
The unadjusted OR for the development of TMA
mong patients treated with sirolimus was 2.79 (95%
I, 1.14-6.84; P .03). The only other factor that was
igniﬁcantly associated with the development of TMA
n univariate analyses was the prior occurrence of
rade II to IV acute GVHD (unadjusted OR, 4.99;
5% CI, 1.99-12.53; P  .0006). Age, malignancy,
tem cell source, and donor type were unrelated to the
evelopment of TMA. In a logistic regression model,
oth sirolimus use (adjusted exact OR, 3.49; 95% CI,
.23-10.42; P .017) and grade II to IV acute GVHD
adjusted exact OR, 6.60; 95% CI, 2.32-20.33; P 
0002) remained statistically signiﬁcantly associated
ith the development of TMA.
ISCUSSION
This retrospective analysis has demonstrated that
he incidence of TMA within 100 days of allogeneic
tem cell transplantation is increased 2.8-fold in sub-
ects who receive sirolimus as primary GVHD pro-
hylaxis. The incidence of TMA in this population
as 10.8%. Sirolimus-associated TMA occurs earlier
fter stem cell transplantation but seems to have a
ore favorable prognosis when compared with TMA
nrelated to sirolimus exposure. This ﬁnding needs to
e conﬁrmed in a larger study because of the small
umber of cases and the large number of potential
onfounding risk factors for TMA that have not been
ncorporated into a survival analysis.
Sirolimus is a novel immunosuppressant in alloge-
eic stem cell transplantation. It is generally well tol-
rated and is not associated with the neurotoxicity and
ephrotoxicity associated with the calcineurin inhibi-
ors. The important toxicities of sirolimus include
eversible myelosuppression, hyperlipidemia [31], and
ulmonary toxicity [14,32,33]. Sirolimus has been
sed as therapy for established acute and chronic
VHD [31,34,35] and now has demonstrated efﬁcacy
s a prophylactic agent [24,25]; it may become rou-
inely used in this setting.
The etiology of sirolimus-induced TMA is un-
nown. The pathologic ﬁnding of diffuse endothelial
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Bnjury is commonly seen, but the mechanisms of this
njury are unclear. One postulated mechanism is en-
anced platelet activation and aggregation leading to
ndothelial damage [36]. Sirolimus may potentiate cal-
ineurin-inhibitor nephrotoxicity via endothelial damage
28], possibly by a sirolimus-induced increase in the
ntrarenal concentration of calcineurin inhibitors [37] or
ia molecular mimicry of tacrolimus. Finally, both siroli-
us and tacrolimus may increase the intrarenal release of
he vasoconstrictor endothelin and lead to direct endo-
helial injury [38]. The syndrome of post-HSCT TMA
s distinct from other classic microangiopathic syn-
romes such as thrombocytopenic purpura, because nor-
al levels of the von Willebrand factor–cleaving pro-
ease ADAMTS13 have been demonstrated in most
osttransplantation microangiopathic cases evaluated for
his marker [13,39-43].
The clinical risk factors for TMA are variable.
ariables related to subject demographics (age and
ex), the stem cell graft donor, the conditioning reg-
men used, and the occurrence of other posttransplan-
ation complications have been reported to inﬂuence
he incidence of TMA [13]. Because cases and controls
ere matched for some of these variables, we are
nable to comment on the potential role of these
actors; however, the use of peripheral blood stem cells
nd unrelated donors did not seem to be related to the
evelopment of TMA. The only factor that inﬂuenced
he development of TMA in our regression model was
he co-occurrence of acute GVHD, which has previously
een reported [9,44-46], although the mechanism of this
ssociation is not understood. We were unable to deter-
ine whether TMA was associated with the co-occur-
ence of VOD of the liver. Many of the patients diag-
osed with VOD were treated with the experimental
gent deﬁbrotide, which may also be effective in the
revention and treatment of TMA [47,48], and were
hus excluded from our analysis. This agent will be the
ocus of a TMA prophylaxis trial in the near future.
ome studies have suggested that the development of
MA is associated with increased levels of immunosup-
ressive agents [26-28]. In our study, before the onset of
MA, immunosuppressant levels both immediately be-
ore and within 2 weeks of the diagnosis of TMA in the
irolimus-exposed and -nonexposed groups were similar
nd were largely within the target therapeutic range
or our institution. Because no difference in the inci-
ence of TMA after tacrolimus or cyclosporine expo-
ure has been reported, subjects receiving either of
hese compounds without sirolimus were analyzed to-
ether.
There are methodologic limitations to this study,
he most important of which is the arbitrary deﬁnition
f TMA we chose. As outlined in a recent review [13],
here is no consensus on a deﬁnition of transplant-
ssociated TMA. Most deﬁnitions include thrombo-
ytopenia and renal insufﬁciency, both of which are a
B&MTommon in the immediate posttransplantation setting.
urthermore, small numbers of schistocytes can also
e seen early after transplantation and are not neces-
arily associated with microangiopathy [49-51]. Fi-
ally, a clinical picture similar to TMA can occur in
ssociation with acute GVHD and systemic infections,
ncluding cytomegalovirus, human herpesvirus 6, ad-
novirus, and aspergillosis [13], all of which occur
requently after allogeneic HSCT.
A second limitation is the retrospective nature of
his study, which looked at patients treated over a
-year period. Although many aspects of transplanta-
ion were unchanged during this interval, bias in this
etting is inevitable. New, less nephrotoxic medica-
ions, including new antifungal medications, were in-
roduced during this time period. HLA typing tech-
iques were also reﬁned, which may have contributed
o a reduced incidence and severity of acute GVHD.
inally, the choice of calcineurin inhibitors changed at
ur institution during the time of the study: tacroli-
us replaced cyclosporine for most patients treated in
ore recent years. Because only patients in the con-
rol arm received cyclosporine, we are unable to de-
ermine whether the choice of a calcineurin inhibitor
s related to the incidence of TMA, but this has not
reviously been reported in the literature.
Ascertainment bias could have inﬂuenced out-
omes in this study. As the use of sirolimus became
ore common at our institution and TMA was rec-
gnized more frequently, the diagnosis was made ear-
ier, and therapeutic interventions were initiated at an
arlier point in the disease course; this may have led to
mproved outcomes. Notably, many patients in the
onsirolimus control population did not have TMA
iagnosed until postmortem examination or until this
eview was performed.
This study highlights the heterogeneity in post-
ransplantation TMA therapy, because no uniform
pproach to the management of these patients was
oted, even within a single transplantation center.
ome subjects only had immunosuppressant medica-
ions adjusted or held, whereas others were treated
ith plasma exchange. Certainly, more critically ill
atients were offered plasma-exchange therapy, the
ole of which is unclear in this population, particularly
hen the etiology of the disorder is likely to be unre-
ated to the presence of antibodies to the ADAMTS13
rotease. In the review reported by George et al. [13],
he use of plasma exchange was associated with an
nferior outcome, which was likely related to a selec-
ion bias of patients offered this therapy rather than to
n effect of the therapy itself. To date, there is no
eported prospective evaluation of plasma exchange
or transplant-related TMA.
In this retrospective study, we have demonstrated
hat sirolimus, when used as GVHD prophylaxis with
calcineurin inhibitor after allogeneic stem cell trans-
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5lantation, is associated with an increased incidence of
MA. Despite this, impaired renal function was re-
ersible in most cases, and there was no negative effect
n overall survival among patients given sirolimus as
rimary prophylaxis for GVHD. It is interesting to
ote that in patients with ongoing TMA related solely
o calcineurin inhibitors, the addition of sirolimus may
ave been implicated in worse outcomes, because 2
atients with calcineurin-related TMA who were
iven sirolimus subsequently died. Because sirolimus
ay become widely used after allogeneic stem cell
ransplantation, we recommend a careful monitoring
trategy by using a prespeciﬁed deﬁnition of TMA to
etect early cases of TMA. We recommend early
ithdrawal of calcineurin inhibitors when TMA is
iagnosed, because this may be sufﬁcient to reverse
he course of TMA. Re-exposure to sirolimus alone
fter the resolution of TMA does seem to be associ-
ted with a relapsing course of TMA.
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